To our knowledge, this is the first reported case of posterior reversible encephalopathy syndrome (PRES) following CD19-directed CAR-T cell therapy for B-ALL successfully managed with medical therapy. This evidence concerns the gene CD19 and acute lymphoblastic leukemia.